BIOCARDIA (OTCMKTS:BCDA) Files An 8-K Regulation FD Disclosure

BIOCARDIA (OTCMKTS:BCDA) Files An 8-K Regulation FD Disclosure
Item 7.01, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that section, nor shall it be deemed to be incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly set forth by specific reference in such filing.

Story continues below

Item 9.01   Financial Statements and Exhibits.

(d) Exhibits

 
 

BioCardia, Inc. Exhibit
EX-99.1 2 ex_228354.htm EXHIBIT 99.1 ex_228354.htm   Exhibit 99.1   FOR IMMEDIATE RELEASE     BIOCARDIA SIGNS AGREEMENT WITH LEADING JAPANESE PHARMACEUTICAL COMPANY FOR CATHETER BIOTHERAPEUTIC DELIVERY PRODUCT CANDIDATES   SAN CARLOS,…
To view the full exhibit click here

About BIOCARDIA (OTCMKTS:BCDA)

BioCardia, Inc., formerly Tiger X Medical, Inc., is a clinical-stage regenerative medicine company. The Company is engaged in developing therapeutics for cardiovascular diseases. The Company’s lead therapeutic candidate is the CardiAMP Cell Therapy System (CardiAMP). It focuses on the Phase III trial for CardiAMP in ischemic systolic heart failure. The Company also offers CardiALLO Cell Therapy System (CardiALLO), an allogeneic off the shelf mesenchymal stem cell product candidate from other donors. It focuses on the Phase II trial for CardiALLO for the treatment of ischemic systolic heart failure. The Company focuses on various fields of autologous and allogeneic cell-based therapies to manage the lives of patients with cardiovascular conditions. CardiAMP is a therapeutic treatment that includes a companion diagnostic. It consists of a cell potency screening test, a point of care cell processing platform and a biotherapeutic delivery system.

An ad to help with our costs